Molecular mechanisms of crizotinib in ROS1-rearranged lung cancer patients. | Download Scientific Diagram
Cell death-based treatment of lung adenocarcinoma | Cell Death & Disease
Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET - Journal of Biological Chemistry
Crizotinib - Wikiwand
eML4–ALK pathways and the mechanism of resistance to crizotinib. Notes:... | Download Scientific Diagram
Frontiers | ALK Inhibitors, a Pharmaceutical Perspective | Oncology
Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death | Haematologica
Crizotinib resistance: implications for therapeutic strategies - Annals of Oncology
Alectinib Hydrochloride
Crizotinib (Xalkori) - Oncology Nurse Advisor
Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET - Lung Cancer
Frontiers | A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer | Oncology
Crizotinib - Wikipedia
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non‐small cell lung cancer - Poon - 2017 - International Journal of Cancer - Wiley Online Library
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. - Abstract - Europe PMC
Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer - Katayama - 2018 - Cancer Science - Wiley Online Library
XALKORI® (crizotinib) - ppt download
Molecular mechanisms of crizotinib resistance in ROS1, depicting the... | Download Scientific Diagram
Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines | Scientific Reports
Cancer Research and Treatment
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non‐small cell lung cancer - Poon - 2017 - International Journal of Cancer - Wiley Online Library
Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer - ScienceDirect
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance | Oncotarget
Agents Targeting ROS1 Gain Traction in NSCLC
Frontiers | Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC | Oncology
